(Q37103948)

18 August 2017

1 reference

title

Combination therapy in the management of mixed dyslipidaemia (English)

1 reference

18 August 2017

1 reference

C P Cannon

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Journal of Internal Medicine

18 August 2017

published in

1 reference

18 August 2017

volume

263

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

353-365

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

High-density lipoprotein as a therapeutic target: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Characteristics of US adults with the metabolic syndrome and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Current overview of statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Antiatherothrombotic effects of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2008.01933.X

10.1111/J.1365-2796.2008.01933.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference